Partner in Transformation

A rare convergence of massive market opportunity, breakthrough technology moat, and measurable social impact.

Why Shiora, Why Now

The Structural Opportunity: Women's health has been systematically underserved for decades. Only 4% of healthcare R&D funding, 75% of clinical trials excluding women, and diagnostic delays averaging 4-7 years for common conditions.

The Market Inflection: We're at a unique moment where AI maturity, consumer demand, regulatory tailwinds, and capital interest are converging. The women's health market is projected to reach $50B+ by 2030, growing at 15%+ CAGR.

The Shiora Advantage: Our ABQS convergence architecture fusing AI, Blockchain, Quantum Computing, and Spatial Intelligence creates compound defensibility impossible to replicate with single-technology approaches.

Core Investment Merits

  • Massive TAM with structural tailwinds
  • Defensible technology moat (ABQS)
  • Multiple revenue streams & exit paths
  • Capital-efficient GTM strategy
  • Measurable impact metrics (ESG/SDG aligned)

"Closing the women's health gap could boost global GDP by $1 trillion annually and add 7 healthy days per woman per year."

Global Institute, 2024

$50B+ Total Addressable Market

Women's health is one of the largest underserved markets in healthcare and one of the fastest growing.

$50B+
Total Addressable Market
by 2030
15%+
Annual Growth Rate
CAGR 2024-2030
3.9B
Women Globally
Underserved population
$1T
GDP Impact
Closing the health gap

Market Segments

Reproductive Health$18.2B
Menopause & Aging$12.4B
Maternal Health$9.8B
Chronic Conditions$7.1B
Mental Wellness$4.5B

Growth Drivers

  • Rising awareness and destigmatization
  • AI/ML enabling personalized care at scale
  • Regulatory push for sex-specific research
  • Corporate benefits expansion (fertility, menopause)
  • Government investment in maternal health
  • Venture capital flowing into FemTech

The ABQS Moat

Our convergence architecture creates compound defensibility that single-technology competitors cannot replicate.

Artificial Intelligence

SANA AI engine with 10M+ training data points. Predictive models for early detection, personalized care pathways.

Blockchain

Immutable health records. Patient-controlled data sovereignty. Transparent consent management.

Quantum Computing

QONTOS partnership for drug discovery, genomic analysis, and complex system modeling.

Spatial Intelligence

3D body mapping, AR-guided self-exams, geographic health pattern analysis.

Why ABQS Creates Unassailable Advantage

Data Network Effects

More users → richer data → better AI → improved outcomes → more users. Flywheel accelerates over time.

Integration Complexity

Competitors would need 4+ years to replicate our convergence stack. By then, our data advantage is insurmountable.

Zhyra Ecosystem

Access to sister companies (QONTOS, Zhilicon) provides technology at cost, accelerating our roadmap.

Multiple Revenue Streams

Diversified monetization across B2C, B2B, and B2B2C channels with strong unit economics.

Consumer Subscriptions

Premium memberships for personalized health insights, AI consultations, and care coordination.

Target ARPU$15-45/mo
Gross Margin75-80%

Enterprise Solutions

White-label platform for employers, health plans, and healthcare systems. Per-member-per-month pricing.

Contract Size$250K-500K/yr
Gross Margin65-70%

Data & Research

Anonymized insights for pharma R&D, clinical trial recruitment, and academic research partnerships.

Partnership Value$100K-2M/yr
Gross Margin85-90%

Government Contracts

Population health infrastructure for ministries of health. National deployment with data sovereignty compliance. Multi-year contracts with expansion options.

Marketplace & Partnerships

Curated marketplace for supplements, devices, and services. Affiliate revenue from telehealth, labs, and pharmacy partners. Transaction fees on care coordination.

Pre-Seed Funding Round

We are raising pre-seed capital to complete product development, achieve regulatory readiness, and execute our go-to-market strategy in the UAE and select international markets.

Use of Funds

40% Product & Engineering
25% Clinical & Regulatory
20% Go-to-Market
15% Operations & G&A

Key Milestones (12-18 Months)

  • MVP launch with 10,000+ beta users
  • 2-3 enterprise pilot agreements
  • HAAD/DOH regulatory approval (UAE)
  • Seed round preparation ($3-5M target)

Pre-Seed Round

$3M

Target raise with SAFE notes

Valuation Cap
$15M
Minimum Check
$250K
Structure
SAFE
Runway
18 Months

Strategic Capital Partners

We seek investors who bring more than capital: strategic value, domain expertise, and long-term alignment with our mission.

Sovereign Wealth Funds

Long-term patient capital aligned with national health and economic diversification priorities. Ideal for government partnerships.

Institutional Investors

Healthcare-focused VCs and growth equity funds seeking exposure to the convergence of AI, digital health, and women's health markets.

UHNW Individuals

Strategic angels with healthcare, technology, or regional expertise. Family offices with multi-generational investment horizons and impact focus.

Impact Investors

ESG-focused funds and foundations seeking measurable outcomes. SDG 3 (Health) and SDG 5 (Gender Equality) alignment with financial returns.

Growth Projections

Conservative base case with significant upside potential as we capture market share in a rapidly expanding sector.

Year 1
$0.2M
ARR
Year 2
$1.2M
ARR
Year 3
$4.5M
ARR
Year 4
$12M
ARR
Year 5
$28M
ARR
500K+
Users by Year 5
70%+
Gross Margin
<18mo
CAC Payback
3.5x
LTV:CAC Ratio

Investment Inquiries

Ready to learn more? Contact our investor relations team to receive our detailed pitch deck, financial model, and schedule a conversation with leadership.

Headquarters

Abu Dhabi, UAE

REQUEST INVESTOR MATERIALS
Disclaimer

This page is for informational purposes only and does not constitute an offer to sell or solicitation of an offer to buy securities. Investment opportunities are available only to accredited investors. Past performance is not indicative of future results. Prospective investors should conduct their own due diligence and consult with financial, legal, and tax advisors before making investment decisions.